Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt.

Faculty Medicine Year: 2018
Type of Publication: ZU Hosted Pages: 421-431
Authors:
Journal: Alimentary Pharmacology & Therapeutics John Wiley & Sons Ltd Volume: 3
Keywords : Generic daclatasvir plus sofosbuvir, with , without    
Abstract:
Background: Treatment of chronic hepatitis C using combination of sofosbuvir (SOF) and daclatasvir (DCV) was used in several clinical trials and multicentre studies, which were somewhat limited to genotypes 1-3. The national program in Egypt is using SOF-DCV combination for large scale treatment. Aim: To assess the efficacy and safety of combined SOF-DCV in treating patients with HCV-G4 in a real-world setting. Methods: Data and outcome of chronic HCV patients who were treated for 12 weeks with generic medications: DCV 60 mg plus SOF 400 mg  ribavirin (RBV) within the national hepatitis C treatment program in Egypt are presented. Treatment- na€ıve patients without cirrhosis were treated without RBV, and those who had cirrhosis or were treatment-experienced (interferon experienced or SOF experienced) received RBV. Efficacy and safety were assessed, and baseline factors associated with sustained virological response at post-treatment week 12 (SVR12) were explored. Results: During the first 2 months of the programme, 18 378 patients with HCVG4 started treatment with SOF-DCV with or without RBV. Overall, 95.1% achieved SVR12 (95.4% among patients treated without RBV and 94.7% for patients treated with RBV, P = .32). Treatment was prematurely discontinued in only 1.5% of patients. The most common events leading to discontinuation were patient withdrawal (n = 76) and pregnancy (n = 5). Five deaths occurred within this group. Conclusions: Real-world experience of generic SOF-DCV in patients with chronic HCV-G4 proved to be safe and associated with a high SVR12 rate, in patients with different stages of fibrosis.
   
     
 
       

Author Related Publications

  • Munkez Mutee Yusuf Muhamed, "دراسة التغيرات فى حركية المرى لدى مرضى التهاب المفاص الرثياخى", لايوجد, 1900 More
  • Munkez Mutee Yusuf Muhamed, "دراسة شكل طفيل بلاستوسيتس هومينيس ودورة الاكلينكى كسبب للاسهال عند المرضى المصابين بخلل فى الجهاز المناعى", لايوجد, 1900 More
  • Munkez Mutee Yusuf Muhamed, "علاقة الارتداد المعدى بالمرى وارتشاح الاذن الوسطى", لايوجد, 1900 More
  • Munkez Mutee Yusuf Muhamed, "دراسة المقاومة لعامل بروتين سى المنشط كعامل خطر لحدوث التجلط فى حالات جلطة الشريان التاجى والمخى", لايوجد, 1900 More
  • Munkez Mutee Yusuf Muhamed, "القيمة التنبؤية لبعض الفحوصات الاكلينكية والمعملية عند مرض الذبحة الصدرية غير المستقرة ودورها فى تقييم المرضى حسب درجات الخطورة", لايوجد, 1900 More

Department Related Publications

  • Ayman Abdalrahman Mohamed Nasrllah, "Thyroid Dysfunction and Inflammatory Biomarkers in COPD:Relation to Severity and Exacerbation", Cairo,Egypt, 2013 More
  • Emad Fawzy Hamed Mahmoud, "ANNEXIN A2 VERSUS AFP AS AN EFFICIENT DIAGNOSTIC SERUM MARKER FOR HEPATOCELLULAR CARCINOMA", المجله المصريه الافريقيه للامراض المتوطنه, 2013 More
  • Ayman Abdalrahman Mohamed Nasrllah, "Fraility:Identification and Markers", London, 2013 More
  • Emad Fawzy Hamed Mahmoud, "Hepatitis C Virus Reactivation in Patients with Heamatological Malignancies, Single Egyptian Center Study", life science journal, 2013 More
  • Emad Fawzy Hamed Mahmoud, "PARAOXONASE 1 Gene Polymorphism Relationship with Type 2 Diabetes Mellitus", life science journal, 2012 More
Tweet